BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
BioVie will host a conference call and webcast on Tuesday, September 15, 2026 at 8:30am ET to discuss topline results from its Phase 2 ADDRESS-LC trial of bezisterim in Long COVID, with UCSF investigator Dr. Michael Peluso and patient advocate Ezra Spier as guest speakers. The roughly 200-patient study was a randomized, placebo-controlled signal-finding proof-of-concept trial with 22 clinical outcome measures, no single pre-specified primary endpoint, and full funding from a $13.13 million U.S. Department of War grant.
Key figures
- Drug Name
- bezisterim (NE3107)
- Phase Of Trial
- Phase 2
- Dosing
- 20 mg oral capsule twice daily
- Itt result
- no endpoint achieved statistical significance; significant results limited to pre-specified subgroups
- Grant source
- U.S. Department of War Peer-Reviewed Medical Research Program (Award No. HT9425-24-1-0113)
- Trial design
- randomized 1:1, placebo-controlled, signal-finding proof-of-concept, multicenter
- Conference call
- September 15, 2026, 8:30am ET
- Outcome measures
- 22
- Primary endpoint
- none pre-specified
- Trial identifier
- NCT06847191
- Enrolled patients
- 203
- Grant funding usd
- 13130000
- Sunrise pd enrollment
- 57
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.